XML 119 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SEGMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Schedule of Information About Reportable Segments and Reconciliation of Segment Net Sales and Pre-Tax Income
The table below presents reconciliations of segment net sales to consolidated net sales and segment operating income to consolidated income before provision for income taxes ("pre-tax income") (in millions):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Net Sales Reconciliation
 

 
 

 
 

Segment net sales
$
4,333.5

 
$
3,676.0

 
$
3,422.1

Foreign currency
14.5

 
46.8

 
13.2

Consolidated net sales
$
4,348.0

 
$
3,722.8

 
$
3,435.3

Pre-tax Income Reconciliation
 

 
 

 
 
Segment operating income
$
2,614.5

 
$
2,115.5

 
$
1,914.6

Unallocated amounts:
 
 
 
 
 
Corporate items
(1,439.7
)
 
(1,058.1
)
 
(903.5
)
Special charges, net
(64.6
)
 
(116.2
)
 
(9.7
)
Intellectual property litigation (expenses) income, net
(33.4
)
 
(214.0
)
 
73.3

Change in fair value of contingent consideration liabilities, net
6.1

 
5.7

 
9.9

Foreign currency
63.9

 
15.3

 
4.8

Consolidated operating income
1,146.8

 
748.2

 
1,089.4

Non-operating income (expense)
19.7

 
13.2

 
(54.5
)
Consolidated pre-tax income
$
1,166.5

 
$
761.4

 
$
1,034.9


The table below presents information about Edwards Lifesciences' reportable segments (in millions):
 
Years Ended December 31,
 
2019
 
2018
 
2017
Segment Net Sales
 

 
 

 
 

United States
$
2,532.7

 
$
2,055.2

 
$
1,907.6

Europe
926.1

 
826.4

 
800.7

Japan
441.4

 
398.4

 
356.5

Rest of World
433.3

 
396.0

 
357.3

Total segment net sales
$
4,333.5

 
$
3,676.0

 
$
3,422.1

Segment Operating Income
 

 
 

 
 
United States
$
1,742.3

 
$
1,368.1

 
$
1,242.3

Europe
472.0

 
394.8

 
378.4

Japan
272.3

 
237.0

 
201.1

Rest of World
127.9

 
115.6

 
92.8

Total segment operating income
$
2,614.5

 
$
2,115.5

 
$
1,914.6


Schedule of Enterprise-Wide Information
Enterprise-wide information is based on actual foreign exchange rates used in the Company's consolidated financial statements.

 
As of or for the Years Ended
December 31,
 
2019
 
2018
 
2017
 
(in millions)
Net Sales by Geographic Area
 

 
 

 
 

United States
$
2,532.7

 
$
2,055.3

 
$
1,907.6

Europe
941.2

 
885.1

 
831.0

Japan
444.7

 
396.8

 
350.3

Rest of World
429.4

 
385.6

 
346.4

 
$
4,348.0

 
$
3,722.8

 
$
3,435.3

Net Sales by Major Product Area
 

 
 

 
 
Transcatheter Aortic Valve Replacement
$
2,737.9

 
$
2,283.8

 
$
2,023.8

Transcatheter Mitral and Tricuspid Therapies
28.2

 
2.9

 
3.4

Surgical Structural Heart
841.7

 
761.6

 
807.1

Critical Care
740.2

 
674.5

 
601.0

 
$
4,348.0

 
$
3,722.8

 
$
3,435.3

Long-lived Tangible Assets by Geographic Area
 

 
 

 
 

United States
$
849.1

 
$
642.1

 
$
608.7

Europe
101.5

 
36.6

 
28.4

Japan
21.7

 
6.7

 
7.6

Rest of World
269.4

 
214.4

 
139.7

 
$
1,241.7

 
$
899.8

 
$
784.4